A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2021-09, Vol.11 (9), p.150-150, Article 150
Hauptverfasser:	Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059 631/67/1990/804 Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Research Correspondence Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Dexamethasone - adverse effects Dexamethasone - therapeutic use Female Hematology Humans Kaplan-Meier Estimate Male Middle Aged Multiple Myeloma - drug therapy Multiple Myeloma - epidemiology Oligopeptides - adverse effects Oligopeptides - therapeutic use Oncology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!